Decree 4725 of 2005<\/strong> regulated medical devices for human use, establishing provisions on:<\/p>\n – Classification of devices according to their risk level For its part, Decree 3770 of 2004 focused specifically on in vitro diagnostic reagents, regulating their evaluation, marketing and surveillance, under a regulatory logic separate from that applied to other medical devices.<\/p>\n Although both decrees played a fundamental role in the organization of the national regulatory system, with the passage of time structural limitations became evident, especially in the face of the lack of integration between medical devices and in vitro reagents, the absence of clear regulation for emerging technologies and the outdatedness of international risk management and product life cycle standards.<\/p>\n The need for a regulatory update<\/strong><\/span><\/p>\n The current healthcare context requires a flexible, dynamic regulatory framework aligned with innovation, capable of responding to the growth of molecular reagents and highly complex tests, the incorporation of software as a medical device (SaMD), the digitalization of diagnostic and clinical processes and the need to strengthen post-marketing surveillance and traceability.<\/p>\n In front of andThese challenges, the Ministry of Health carried out a Regulatory Impact Analysis (AIN) that concluded in the need to repeal and replace Decrees 4725 and 3770, consolidating a new unified decree that modernizes the health regulation of these technologies. The main axes of the new regulatory approach are:<\/p>\n 1. Integration of medical devices and in vitro reagents: <\/strong>One of the most relevant changes is the explicit recognition of in vitro diagnostic reagents as a category of medical devices, eliminating regulatory fragmentation and allowing more coherent and systematic regulation.<\/p>\n 2. Risk-based and lifecycle approach: <\/strong>The new regime adopts an approach aligned with international best practice, considering risk assessment according to intended use, control from manufacturing to end use, strengthening post-market surveillance and management of adverse events and incidents. This approach allows regulatory resources to be prioritized and improve the protection of patients and users.<\/p>\n 3. Inclusion of emerging technologies: <\/strong>The updated regulations incorporate devices that were not clearly regulated in previous decrees, such as:<\/p>\n – Software as a medical device This represents a significant advance for a health system seeking to adapt to digital transformation.<\/p>\n 4. Clarity in roles and responsibilities: <\/strong>The new decree more precisely defines the obligations of manufacturers, importers, holders of health records, <\/strong>distributors and health service providers.<\/p>\n This clarity strengthens regulatory compliance and facilitates the inspection, surveillance and control processes by INVIMA.<\/p>\n Implications for the health sector and the clinical laboratory<\/strong><\/span><\/p>\n For actors in the health sector, especially the clinical laboratory<\/strong>, this regulatory update implies:<\/p>\n – Greater legal security Likewise, it represents an opportunity to promote innovation<\/strong>, always under standards of quality, safety and effectiveness.<\/p>\n Conclusion<\/strong><\/span><\/p>\n The update of the regulatory framework that was historically supported by Decrees 4725 of 2005 and 3770 of 2004 represents much more than a legal adjustment, it constitutes a redefinitionof the Colombian regulatory model for medical devices and in vitro diagnostic reagents. This transition responds to the need for health regulation to evolve at the same pace as scientific, technological and clinical innovation, avoiding delays that could compromise patient safety or limit the development of the sector.<\/p>\n The new regulatory approach, based on risk management, control throughout the product life cycle and the integration of emerging technologies, allows strengthening the State’s capacity to guarantee the quality, safety and performance of these health technologies. At the same time, it offers a clearer and more predictable framework for manufacturers, importers, health registration holders and health service providers, reducing regulatory uncertainty and promoting responsible compliance.<\/p>\n For clinical laboratory and diagnostic services, this update takes on particular relevance. The formal incorporation of in vitro reagents within a unified medical device regimen that facilitates better traceability, more effective post-market surveillance and a more rigorous evaluation of the risks associated with the use of diagnostic tests, especially those of high complexity, clinical impact and therapeutic decision support.<\/p>\n Likewise, this modernization process opens the door to greater harmonization with international regulatory standards, which not only strengthens confidence in the national health system, but also positions Colombia as a more attractive environment for research, development and the introduction of innovative health technologies. In a global context where timely diagnosis and precision medicine are fundamental pillars, having robust and updated regulation becomes a strategic element.<\/p>\n
\n– Requirements for obtaining health registration
\n– Obligations of manufacturers, importers and marketers
\n– Sanitary surveillance and control by INVIMA<\/p>\n![\"\"](\"https:\/\/invitronews.com\/wp-content\/uploads\/2026\/01\/IMAGEN-1_IN-VITRO_DECRETO-4725-270x300.png\")
<\/p>\n![\"\"](\"https:\/\/invitronews.com\/wp-content\/uploads\/2026\/01\/IMAGEN-2_IN-VITRO_DECRETO-4725-270x300.png\")
<\/p>\n![\"\"](\"https:\/\/invitronews.com\/wp-content\/uploads\/2026\/01\/IMAGEN-3_IN-VITRO_DECRETO-4725-270x300.png\")
<\/p>\n
\n– Digital technologies applied to diagnosis
\n– Innovations in reagents and automated platforms<\/p>\n
\n– Clearer processes for acquiring and using technologies
\n– Improvement in the quality and reliability of diagnostic reagents
\n– Strengthening traceability and risk management<\/p>\n![\"\"](\"https:\/\/invitronews.com\/wp-content\/uploads\/2026\/01\/IMAGEN-4_IN-VITRO_DECRETO-4725-e1767809293740-450x300.png\")
<\/p>\n